Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine

Completed

Conditions studied: Treatment Resistant Depression

In brief

This study aims to assess the efficacy and safety of intranasal esketamine as maintenance antidepressant therapy in patients who have demonstrated clinical improvement with off-label intravenous racemic ketamine for treatment-resistant depression.

Key facts

Study ID

NCT04856124

Run by

Psych Atlanta

People needed

10

Starts

2018-09-01

Expected to finish

2021-03-01

Last updated by the study team

2021-04-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Diagnosis of major depression, recurrent, severe without psychotic symptoms according to criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V). Must be diagnosed with Treatment resistant depression.
• 18 years old and up Patients had a clinically meaningful response to a course of IV racemic ketamine

You may not qualify if…

• Active substance abuse, psychosis, significant medical comorbidities, or axis II diagnosis that would interfere with the reliability of outcome measures or response to pharmacotherapy.

Where it is running

• PsychAtlanta — Marietta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.